Mayne Pharma Group (ASX:MYX) Short-Term Debt : A$0.0 Mil (As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Mayne Pharma Group Short-Term Debt?

Mayne Pharma Group's Short-Term Debt for the quarter that ended in Jun. 2024 was A$0.0 Mil.

Mayne Pharma Group's quarterly Short-Term Debt declined from Jun. 2023 (A$10.8 Mil) to Dec. 2023 (A$3.5 Mil) and declined from Dec. 2023 (A$3.5 Mil) to Jun. 2024 (A$0.0 Mil).

Mayne Pharma Group's annual Short-Term Debt declined from Jun. 2022 (A$405.4 Mil) to Jun. 2023 (A$10.8 Mil) and declined from Jun. 2023 (A$10.8 Mil) to Jun. 2024 (A$0.0 Mil).

Mayne Pharma Group Short-Term Debt Historical Data

The historical data trend for Mayne Pharma Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Short-Term Debt Chart

Mayne Pharma Group Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Debt

Get a 7-Day Free Trial

44.84

51.16

405.37

10.81

Mayne Pharma Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Short-Term Debt	Get a 7-Day Free Trial															405.37	76.90	10.81	3.47	-

Mayne Pharma Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Mayne Pharma Group Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

MAYNF:USA HG6:Germany HG6:Germany

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.